Moneta Group Investment Advisors LLC decreased its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 56.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,526 shares of the biopharmaceutical company’s stock after selling 5,954 shares during the period. Moneta Group Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $353,000 as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. Private Ocean LLC bought a new stake in Bristol-Myers Squibb in the first quarter worth about $28,000. James Investment Research Inc. raised its position in Bristol-Myers Squibb by 36.5% in the first quarter. James Investment Research Inc. now owns 819 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 219 shares during the period. Endurance Wealth Management Inc. raised its position in Bristol-Myers Squibb by 119.6% in the second quarter. Endurance Wealth Management Inc. now owns 918 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 500 shares during the period. SeaBridge Investment Advisors LLC raised its position in Bristol-Myers Squibb by 47.4% in the first quarter. SeaBridge Investment Advisors LLC now owns 933 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 300 shares during the period. Finally, HMS Capital Management LLC bought a new stake in Bristol-Myers Squibb in the second quarter worth about $45,000. 80.27% of the stock is currently owned by institutional investors and hedge funds.
BMY has been the topic of several research reports. Argus lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price objective on the stock. in a research report on Monday, May 20th. Bank of America lifted their target price on shares of Bristol-Myers Squibb from $46.00 to $49.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 3rd. ValuEngine upgraded shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research note on Monday, August 26th. Atlantic Securities upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price for the company in a research note on Wednesday, August 14th. Finally, Goldman Sachs Group assumed coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, May 28th. They issued a “buy” rating and a $54.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $55.74.
In other news, Director Robert J. Bertolini acquired 11,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, July 31st. The stock was bought at an average price of $44.72 per share, with a total value of $491,920.00. Following the completion of the purchase, the director now owns 11,397 shares in the company, valued at $509,673.84. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.13% of the stock is currently owned by insiders.
Shares of BMY traded up $0.73 during trading hours on Thursday, hitting $49.97. The company’s stock had a trading volume of 320,807 shares, compared to its average volume of 15,978,581. The business has a 50 day simple moving average of $46.87 and a two-hundred day simple moving average of $47.14. The company has a market cap of $80.55 billion, a price-to-earnings ratio of 12.55, a PEG ratio of 2.37 and a beta of 0.70. Bristol-Myers Squibb Co has a 52-week low of $42.48 and a 52-week high of $63.69. The company has a debt-to-equity ratio of 1.51, a current ratio of 3.88 and a quick ratio of 3.75.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, beating the consensus estimate of $1.06 by $0.12. The company had revenue of $6.27 billion during the quarter, compared to analysts’ expectations of $6.10 billion. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. Bristol-Myers Squibb’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.01 earnings per share. Research analysts predict that Bristol-Myers Squibb Co will post 4.28 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be paid a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a yield of 3.28%. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.